Abstract
The COVID-19 (SARS-CoV-2) pandemic has led to a significant number of deaths globally and negative health consequences. Accurate early diagnosis, surveillance, identification of cohorts, and prophylaxis are considered essential measures to reduce the spread of SARS-CoV-2. There is a need for a reliable, fast, high-throughput screening method that can identify sick patients. Since respiratory viruses are typically present in nasal and oral secretions, saliva would be a good target for testing. Polymerase chain reaction (PCR) remains the gold standard for sensitive detection of SARS-CoV-2 infection in biological samples. Although PCR testing for COVID is sensitive (500 virions per ml) and widely used by hospitals, the method has a false-negative rate of 15–20% and is kit based. Saliva testing has slowly gained popularity in the diagnostic market for testing based on biomarkers and other constituents ranging from organic compounds (e.g., food additives), peptides, and even microorganisms. In this paper, we will show how the SpecID Mass Spectrometer can detect the presence of a virus in saliva at very low levels. The main goal of the study consisted of addressing the shortcomings of existing methodologies, by providing a reliable, high-throughput, rapid, modified mass spectrometer to detect viruses in saliva, including but not limited to SARS-CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported in its entirety by the U.S. Food and Drug Administration.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Having obtained FDA IRB approval, the saliva used in this study was collected from consenting healthy human volunteers and used to prepare the various viral suspensions analyzed. Volunteers at our facility, who agreed to participate in our study, provided saliva in 1.5 mL microcentrifuge tubes at least 60 min after the most recently ingested meal. The volunteers have provided us with a signed hard-copy consent form, which we have a copy of.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
